Table 5. Analysis of variance for costs... | American Society of Hematology

Table 5.

Analysis of variance for costs and length of stay

Variables^5-150	Cost			Length of stay
Variables^5-150	Ratio	95% CI	P	Ratio	95% CI	P
T-cell depletion vs immunosuppressive medications	0.73	0.63 -0.84	< .001	0.81	0.71 -0.93	.004
Age, older than 50 y vs 50 y or younger	1.04	0.90 -1.20	.60	1.05	0.91 -1.20	.47
High-risk disease vs low-risk disease	1.22	1.05 -1.40	.01	1.21	1.05 -1.39	.01
Male patient/female donor vs other	1.20	1.02 -1.40	.03	1.19	1.02 -1.38	.03
HLA-mismatched vs HLA-matched	1.08	0.88 -1.32	.46	0.97	0.80 -1.19	.80
Patient CMV serologic status negative vs positive	0.86	0.75 -0.99	.03	0.88	0.77 -1.00	.05

Variables^5-150	Cost			Length of stay
Variables^5-150	Ratio	95% CI	P	Ratio	95% CI	P
T-cell depletion vs immunosuppressive medications	0.73	0.63 -0.84	< .001	0.81	0.71 -0.93	.004
Age, older than 50 y vs 50 y or younger	1.04	0.90 -1.20	.60	1.05	0.91 -1.20	.47
High-risk disease vs low-risk disease	1.22	1.05 -1.40	.01	1.21	1.05 -1.39	.01
Male patient/female donor vs other	1.20	1.02 -1.40	.03	1.19	1.02 -1.38	.03
HLA-mismatched vs HLA-matched	1.08	0.88 -1.32	.46	0.97	0.80 -1.19	.80
Patient CMV serologic status negative vs positive	0.86	0.75 -0.99	.03	0.88	0.77 -1.00	.05

Excludes one patient missing cost and days of hospitalization data due to research administrative error.

CI indicates confidence interval; HLA, human leukocyte antigen; and CMV, cytomegalovirus.

F5-150

Reference groups: immunosuppressive medications, age ≤ 50 years, low-risk disease, other than male patient/female donor, HLA-matched, patient CMV serologic status positive.

View Large

This Feature Is Available To Subscribers Only